Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Pancreatic Cancer: early-phase trial registry
14 of 33 indexed Metastatic Pancreatic Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #463 of 28,707 conditions by registered trial count.
33 US clinical trials · 14 currently recruiting · #463 of 28,707 conditions by registered trial count
Metastatic Pancreatic Cancer: 33 US clinical trials tracked, 14 recruiting.
Metastatic Pancreatic Cancer is the subject of 33 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Fox Chase Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-pancreatic-cancer
OPEN 14 | RECR 42% | LATE 2 | EARLY 27 | RANK #463 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Idiopathic Pulmonary Fibrosis (42% recruiting · 52 trials)
Metastatic Pancreatic Cancer lists 14 open slots (42% of 33 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Pancreatic Cancer is recruiting above its size-band peers.
14 of 33 indexed trials (42.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Pancreatic Cancer trials is spread across many organizations.
Fox Chase Cancer Center accounts for 2 of 33 trials (6.1%). 26 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Pancreatic Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 33 trials that report a genuine target (sentinel values excluded). 25 of those (75.8%) plan for fewer than 100 participants.
-
Metastatic Pancreatic Cancer research is mostly interventional.
32 interventional and 1 observational studies make up this index (97% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
33 total, page 1 of 1
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Global Development
NCT07409272
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Quercis Pharma
NCT06861088
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT01174121
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT04222413
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
UNC Lineberger Comprehensive Cancer Center
NCT06483555
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT03682289
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
ImmunoGenesis
NCT06782555
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
NCT04605913
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04753879
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Alpha Tau Medical
NCT06698458
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
Cantex Pharmaceuticals
NCT05766748
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
University of California, Davis
NCT04665947
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology
NCT04150042
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Benjamin Spieler
NCT06843551
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Astellas Pharma Global Development
NCT03816163
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
Fox Chase Cancer Center
NCT05360732
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
Georgetown University
NCT05827055
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
Massachusetts General Hospital
NCT04361162
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Lyudmyla Berim
NCT04672005
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
University of Arizona
NCT04820179
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT06168812
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
SynerGene Therapeutics
NCT02340117
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy
Northwell Health
NCT07122466
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Memorial Sloan Kettering Cancer Center
NCT05642962
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Halozyme Therapeutics
NCT01839487
Improving Informed Consent for Palliative Chemotherapy
Dana-Farber Cancer Institute
NCT02282722
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
Yale University
NCT01523457
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
R-Pharm
NCT00383149
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Brown University
NCT02080221
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
Fox Chase Cancer Center
NCT00761345
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
Brown University
NCT00439179
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
NCT04409002
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
Dana-Farber Cancer Institute
NCT03602885
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 17 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Pancreatic Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Pancreatic Cancer page
33 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Metastatic Pancreatic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fox Chase Cancer Center sponsors the most Metastatic Pancreatic Cancer trials on record, review their full trial history before evaluating a specific study. See Fox Chase Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Pancreatic Cancer condition card totals 33 registered trials; most-linked intervention Gemcitabine; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.